164 related articles for article (PubMed ID: 35340014)
21. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
[TBL] [Abstract][Full Text] [Related]
22. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.
Baxter EJ; Kulkarni S; Vizmanos JL; Jaju R; Martinelli G; Testoni N; Hughes G; Salamanchuk Z; Calasanz MJ; Lahortiga I; Pocock CF; Dang R; Fidler C; Wainscoat JS; Boultwood J; Cross NC
Br J Haematol; 2003 Jan; 120(2):251-6. PubMed ID: 12542482
[TBL] [Abstract][Full Text] [Related]
23. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J
Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975
[TBL] [Abstract][Full Text] [Related]
24. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
[TBL] [Abstract][Full Text] [Related]
25. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
[TBL] [Abstract][Full Text] [Related]
26. Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.
Di Giacomo D; Quintini M; Pierini V; Pellanera F; La Starza R; Gorello P; Matteucci C; Crescenzi B; Fiumara PF; Veltroni M; Borlenghi E; Albano F; Forghieri F; Maccaferri M; Bettelli F; Luppi M; Cuneo A; Rossi G; Mecucci C
Ann Hematol; 2022 Feb; 101(2):297-307. PubMed ID: 34859285
[TBL] [Abstract][Full Text] [Related]
27. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
[TBL] [Abstract][Full Text] [Related]
28. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
Savage N; George TI; Gotlib J
Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
[TBL] [Abstract][Full Text] [Related]
29. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.
Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH
Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582
[TBL] [Abstract][Full Text] [Related]
30. Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in children.
Berking AC; Flaadt T; Behrens YL; Yoshimi A; Leipold A; Holzer U; Lang P; Quintanilla-Martinez L; Schlegelberger B; Reiter A; Niemeyer C; Strahm B; Göhring G
Cancer Genet; 2023 Apr; 272-273():29-34. PubMed ID: 36657267
[TBL] [Abstract][Full Text] [Related]
31. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
Gallagher G; Horsman DE; Tsang P; Forrest DL
Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053
[TBL] [Abstract][Full Text] [Related]
32. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.
Shimomura Y; Maruoka H; Ishikawa T
Int J Hematol; 2017 May; 105(5):697-701. PubMed ID: 28000100
[TBL] [Abstract][Full Text] [Related]
33. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
[No Abstract] [Full Text] [Related]
34. A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
Iriyama N; Takahashi H; Naruse H; Miura K; Uchino Y; Nakagawa M; Iizuka K; Hamada T; Hatta Y; Nakayama T; Takei M
Mol Genet Genomic Med; 2019 Apr; 7(4):e00591. PubMed ID: 30697976
[TBL] [Abstract][Full Text] [Related]
35. [Successful treatment with imatinib for a patient with myeloid neoplasms with eosinophilia and abnormalities of PDGFRB due to t (5;14)(q33;q22)].
Fujii T; Ohno N; Matsui T; Kitahara S; Kobayashi S; Sahara N; Sakamoto N; Matsunaga T
Rinsho Ketsueki; 2021; 62(11):1635-1638. PubMed ID: 34866089
[TBL] [Abstract][Full Text] [Related]
36. [Myeloid neoplasms associated with rearrangement of PDGFRB: A rare and tricky disease].
Bontoux C; Badaoui B; Abermil N; Tarfi S; Guermouche H; Dubois S; Roy L; Xuan JV; Quang VT; Wang L; Favre L; Poullot E; Michel M; Sloma I; Crickx E; Pécriaux A
Ann Pathol; 2022 Nov; 42(6):481-487. PubMed ID: 36050197
[TBL] [Abstract][Full Text] [Related]
37. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
38. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
Cheah CY; Burbury K; Apperley JF; Huguet F; Pitini V; Gardembas M; Ross DM; Forrest D; Genet P; Rousselot P; Patton N; Smith G; Dunbar CE; Ito S; Aguiar RC; Odenike O; Gimelfarb A; Cross NC; Seymour JF
Blood; 2014 Jun; 123(23):3574-7. PubMed ID: 24687085
[TBL] [Abstract][Full Text] [Related]
39. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
40. Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features.
Su Z; Liu X; Hu W; Yang J; Yin X; Hou F; Wang Y; Zhang J
Hematology; 2022 Dec; 27(1):1010-1018. PubMed ID: 36069745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
